Last checked at 
(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:
----------
N4 Pharma PLC - Derbyshire-based specialist pharmaceutical company focused on a delivery system for oncology, gene therapy and vaccines - Launches new interactive investor hub, which it says brings all N4 Pharma content into a "single integrated platform to better inform and engage with investors and stakeholders." This includes regulatory announcements, annual and interim reports and corporate presentations. Also provides an interactive online experience allowing the company's stakeholders to comment on and ask the N4 Pharma team questions via a portal. Founder & Chief Executive Officer Nigel Theobald says: "At N4 Pharma, we have always encouraged our shareholders to engage with us. We see Investor Hub as an effective platform upon which to further enable our shareholders, and potential shareholders to interact with N4 Pharma. Investor Hub will give us a platform to collate all our video material, information and insights about our activities and plans in one place."
----------
Capricorn Energy PLC - Egypt-focused upstream energy company - Says working interest production across the four main concession areas in the Western Desert averaged 30,600 of barrels of oil equivalent per day for the year. Says that due to delays in the first half of the year, 2023 production will be below guidance at around 30,000 boepd. Adds its capex and opex guidance remains unchanged at USD117-127 million and USD5-6 per boe.
----------
San Leon Energy PLC - Nigeria-focused oil and gas production, development and exploration company - Says Oza field receives approval for exports through Trans Niger pipeline. Holds 11% stake in Decklar, which operates Oza field.
----------
PureTech Health PLC - Boston, Massachusetts-based FTSE 250 biotechnology company - Says founded entity Karuna Therapeutics receives US Food and Drug Administration acceptance for schizophrenia treatment KarXT application. Says if approved, KarXT would be the first new pharmacological approach to treating schizophrenia in "several decades". The application is supported by positive data from the Emergent clinical trial programme.
----------
Cadence Minerals PLC - London-based investor backing mineral resource assets - Notes that Evergreen Lithium Ltd's has announced the first batch of assay results from soil sampling at Bynoe in the Northern Territory which has identified new large and significant lithium anomalism. Cadence holds around 8.7% in issued share capital of Evergreen. Evergreen Chair Simon Lill comments: "Geochemical results from sample analysis at central Bynoe is significant as it points to additional zones of interest further south-east from those identified along the core lithium boundary, announced previously. Our latest mapping program across the geochemical anomalies and [ambient noise tomography] survey targets, has identified structures hosting quartz veins with intermittent muscovite, which may be using the same structures as the pegmatite targets. The upcoming drill program, expected to commence shortly, will test several geochemical anomalies, ANT survey targets and depth extensions."
----------
SolGold PLC - Ecuador-focused copper and gold exploration company - Advances exploration across cluster of porphyry copper-gold targets at Porvenir project in the south-eastern portion of the Eastern Cordillera of Ecuador. Geology manager Santiago Vaca says: "Drilling completed in the Cacharposa deposit indicates a pit constrained mineral resource, which is still open. The successful exploration performed at Cacharposa allows us to enhance our understanding on the geology and mineralization controls in the area, building our confidence in the potential to keep growing the resource with additional drilling, and to validate the high-quality of the other Cu-Au porphyry targets found within the Porvenir project".
----------
By Sabrina Penty, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
